Study of RP-6306 in Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Advanced Solid Tumor
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 12 years and 125 years
- Gender
- Both males and females
Description
Phase 1, multi-center, open-label, dose-escalation study to: Evaluate the safety profile and MTD of RP-6306 when administered orally to establish the recommended Phase 2 dose and schedule Characterize the PK and pharmacodynamics of RP-6306 monotherapy Assess preliminary anti-tumor activity associate...
Phase 1, multi-center, open-label, dose-escalation study to: Evaluate the safety profile and MTD of RP-6306 when administered orally to establish the recommended Phase 2 dose and schedule Characterize the PK and pharmacodynamics of RP-6306 monotherapy Assess preliminary anti-tumor activity associated with RP-6306 monotherapy
Tracking Information
- NCT #
- NCT04855656
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon